HRP20200605T1 - Farmaceutske kompozicije za liječenje inflamatornih poremećaja - Google Patents

Farmaceutske kompozicije za liječenje inflamatornih poremećaja Download PDF

Info

Publication number
HRP20200605T1
HRP20200605T1 HRP20200605TT HRP20200605T HRP20200605T1 HR P20200605 T1 HRP20200605 T1 HR P20200605T1 HR P20200605T T HRP20200605T T HR P20200605TT HR P20200605 T HRP20200605 T HR P20200605T HR P20200605 T1 HRP20200605 T1 HR P20200605T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical composition
composition according
diseases
compound
weight
Prior art date
Application number
HRP20200605TT
Other languages
English (en)
Inventor
Marc Maurice Germain De Weer
Sara Bertha Camiel Vrielynck
Nicolas Luc Sabourault
Jan Peter Moeschwitzer
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of HRP20200605T1 publication Critical patent/HRP20200605T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Claims (14)

1. Farmaceutska kompozicija koja sadrži: (i) 1-50% po masi soli klorovodične kiseline spoja 1: [image] (ii) najmanje 49.9% po masi inertnog čvrstog razblaživača odabranog od celuloze u prahu, silicificiranog acetata mikrokristalne celuloze, kompresibilnog šećera, konditorskog šećera, kukuruznog škroba i preželatiniziranog škroba, dekstrata, dekstrina, dekstroze, eritritola, etilceluloze, fruktoze, fumarne kiseline, gliceril palmitostearata, inhalacione laktoze, izomalta, kaolina, laktitola, laktoze, kukuruznog škroba, mikrokristalne celuloze, maltodekstrina, maltoze, manitola, triglicerida srednjeg lanca, polidekstroze, polimetakrilata, simetikona, sorbitola, preželatiniziranog škroba, sterilizabilnog kukuruza, saharoze, šećernih sfera, sulfobutiletar β-ciklodekstrina, talka, tragakante, trehaloze, i ksilitola; (iii) 0.1-5% po masi nejonskog lubrikanta odabranog od ulja kanole, hidrogenizovanog ricinusovog ulja, ulja sjemenki pamuka, gliceril behenata, gliceril monostearata, gliceril palmitostearata, triglicerida srednjeg lanca, mineralnog ulja, lakog mineralnog ulja, oktildodekanola, poloksamera, polietilen glikola, polioksietilen stearata, polivinil alkohola, škroba, i hidrogeniziranog biljnog ulja, (iv) 0.1 do 5% po masi nejonskog sredstva za raspadanje odabranog od alginske kiseline, celuloze u prahu, hitozana, koloidnog silicij dioksida, kukuruznog škroba i preželatiniziranog škroba, krospovidona, glicina, guar gume, nisko-supstituirane hidroksipropil celuloze, metilceluloze, mikrokristalne celuloze, i povidona, i (v) 0.1 do 0.5% po masi glidanta odabranog od celuloze u prahu, koloidnog silicij dioksida, hidrofobne koloidne silike, silicij dioksida, i talka.
2. Farmaceutska kompozicija prema patentnom zahtjevu 1, gdje inertni čvrsti razblaživač je mikrokristalna celuloza.
3. Farmaceutski lubrikant prema bilo kojem od patentnog zahtjeva 1, gdje lubrikant je biljno ulje, glicerol dibehenat, ili polietilen glikol 10,000.
4. Farmaceutska kompozicija prema patentnom zahtjevu 1, gdje sredstvo za raspadanje je polivinilpolipirolidon, preželatinizirani škrob, ili mikrokristalna celuloza.
5. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-4, gdje sol klorovodične kiseline spoja 1 je 1:1:3 [spoj 1:HCl:H2O] adukt.
6. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-5, gdje sol klorovodične kiseline spoja 1 je u čvrstom kristalnom obliku.
7. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-6, gdje sol klorovodične kiseline spoja 1, gdje je sol naznačena najmanje pomoću pika rendgenske difrakcije na prahu u svim od slijedećih položaja: 7.3, 8.4, 8.8, 10.7, 12.0, 12.2, 13.2, 13.7, 14.5, 16.3, 16.7, 17.6, 19.3, 20.2, 20.6, 21.0, 21.4, 21.8, 22.8, 23.4, 23.9, 24.5, 25.2, 25.7, 25.9, 26.4, 27.2, 27.7, 28.3, 28.6, 28.9, 29.2, 29.6, 7 i 32.7° 2θ ± 0.2° 2θ.
8. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-7, koja sadrži dodatni terapijski agens.
9. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-7, koja je u obliku tablete.
10. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-7, koja je u obliku kapsule.
11. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-10, za primjenu u medicini.
12. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-10, za primjenu u preventivi i/ili liječenju inflamatornih stanja, autoimunih bolesti, proliferativnih bolesti, alergije, odbacivanja transplanta, bolesti koje uključuju degradaciju i/ili poremećaj homeostaze hrskavice, kongenitalnih malformacija hrskavice, i/ili bolesti povezanih sa hipersekrecijom IL6 ili interferona.
13. Kompozicija za primjenu prema patentnom zahtjevu 11 ili 12, gdje farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-10 se administrira u kombinaciji sa drugim terapijskim agensom.
14. Farmaceutska kompozicija prema patentnom zahtjevu 8, ili kompozicija za primjenu prema patentnom zahtjevu 13, gdje dodatni terapijski agens je agens za preventivu i/ili liječenje inflamatornih stanja, autoimunih bolesti, proliferativnih bolesti, alergije, odbacivanja transplanta, bolesti koje uključuju degradaciju i/ili poremećaj homeostaze hrskavice, kongenitalne malformacije hrskavice, i/ili bolesti povezane sa hipersekrecijom IL6 ili interferona.
HRP20200605TT 2014-02-07 2020-04-16 Farmaceutske kompozicije za liječenje inflamatornih poremećaja HRP20200605T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201402070A GB201402070D0 (en) 2014-02-07 2014-02-07 Pharmaceutical compositions for the treatment of inflammatory disorders
EP15705777.9A EP3102213B1 (en) 2014-02-07 2015-02-04 Pharmaceutical compositions for the treatment of inflammatory disorders
PCT/EP2015/052239 WO2015117980A1 (en) 2014-02-07 2015-02-04 Pharmaceutical compositions for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
HRP20200605T1 true HRP20200605T1 (hr) 2020-07-10

Family

ID=50390571

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200605TT HRP20200605T1 (hr) 2014-02-07 2020-04-16 Farmaceutske kompozicije za liječenje inflamatornih poremećaja

Country Status (14)

Country Link
US (1) US10493158B2 (hr)
EP (1) EP3102213B1 (hr)
JP (1) JP6633531B2 (hr)
AR (1) AR099306A1 (hr)
AU (1) AU2015215044B2 (hr)
CA (1) CA2938217C (hr)
DK (1) DK3102213T3 (hr)
ES (1) ES2788671T3 (hr)
GB (1) GB201402070D0 (hr)
HR (1) HRP20200605T1 (hr)
NZ (1) NZ722403A (hr)
TW (1) TWI697330B (hr)
UY (1) UY35985A (hr)
WO (1) WO2015117980A1 (hr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105198876B (zh) * 2015-09-18 2017-09-29 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物h晶型及其制备方法
CN105198879B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物c晶型及其制备方法
CN105198878B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物f晶型及其制备方法
CN105198877B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物g晶型及其制备方法
CN105198880B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物a晶型及其制备方法
CN105111206B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物e晶型及其制备方法
CN105111207B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物d晶型及其制备方法
CN105218539B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物b晶型及其制备方法
SG10202112628UA (en) * 2015-11-30 2021-12-30 Anacor Pharmaceuticals Inc Topical pharmaceutical formulations for treating inflammatory-related conditions
CN109071531A (zh) * 2016-03-21 2018-12-21 苏州晶云药物科技股份有限公司 用于治疗或预防jak相关疾病药物的盐酸盐晶型及其制备方法
EP3538103A1 (en) 2016-11-10 2019-09-18 Galapagos NV Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
GB201702603D0 (en) 2017-02-17 2017-04-05 Galápagos Nv Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JOP20180018A1 (ar) 2017-03-14 2019-01-30 Gilead Sciences Inc تركيبات صيدلية تتضمن مثبط jak
EP3758708A1 (en) * 2018-03-01 2021-01-06 AstraZeneca AB Pharmaceutical compositions comprising (2s)--{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
GB201808575D0 (en) * 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500854B1 (en) 1999-01-29 2002-12-31 Chugai Sei Yaku Kabushiki Kaisha Chondrongenesis promotors and indolin-2-one derivatives
JPWO2002087620A1 (ja) 2001-04-27 2004-08-12 中外製薬株式会社 軟骨形成促進剤
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
ES2264795T3 (es) 2003-02-14 2007-01-16 Pfizer Products Inc. Triazolo-piridinas como compuestos antiinflamatorios.
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
ES2427046T3 (es) 2004-06-21 2013-10-28 Galapagos N.V. Métodos y medios para el tratamiento de la osteoartritis
WO2006018735A2 (en) 2004-08-18 2006-02-23 Pharmacia & Upjohn Company Llc Triazolopyridine compounds
US7524860B2 (en) 2004-10-07 2009-04-28 Pfizer Inc. Antibacterial agents
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
WO2007018192A1 (ja) * 2005-08-10 2007-02-15 Shionogi & Co., Ltd. 口腔内崩壊錠剤
SG174086A1 (en) 2006-08-30 2011-09-29 Cellzome Ltd Triazole derivatives as kinase inhibitors
AR066845A1 (es) 2007-06-05 2009-09-16 Takeda Pharmaceutical Derivados de triazolopiridina e imidazopiridina una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento del cancer
KR20100049073A (ko) 2007-07-18 2010-05-11 노파르티스 아게 비시클릭 헤테로아릴 화합물 및 키나제 억제제로서의 그의 용도
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
CA2691448A1 (en) 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP5595389B2 (ja) 2008-06-20 2014-09-24 ジェネンテック， インコーポレイテッド トリアゾロピリジンｊａｋ阻害剤化合物と方法
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
EP2438066A2 (en) 2009-06-05 2012-04-11 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
PL2863950T3 (pl) 2012-06-22 2019-02-28 Galapagos Nv Aminotriazolopirydyna do zastosowania w leczeniu zapalenia i jej kompozycje farmaceutyczne
JP6041823B2 (ja) * 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
GB201402071D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
GB201402070D0 (en) 2014-03-26
US20150224199A1 (en) 2015-08-13
AR099306A1 (es) 2016-07-13
JP6633531B2 (ja) 2020-01-22
AU2015215044B2 (en) 2020-04-09
AU2015215044A1 (en) 2016-08-11
JP2017505330A (ja) 2017-02-16
US10493158B2 (en) 2019-12-03
CA2938217A1 (en) 2015-08-13
TW201613601A (en) 2016-04-16
TWI697330B (zh) 2020-07-01
WO2015117980A1 (en) 2015-08-13
EP3102213B1 (en) 2020-04-01
UY35985A (es) 2015-09-30
DK3102213T3 (da) 2020-05-04
CA2938217C (en) 2023-03-07
EP3102213A1 (en) 2016-12-14
NZ722403A (en) 2019-09-27
ES2788671T3 (es) 2020-10-22

Similar Documents

Publication Publication Date Title
HRP20200605T1 (hr) Farmaceutske kompozicije za liječenje inflamatornih poremećaja
JP2017505330A5 (hr)
JP2018507200A5 (hr)
JP2009509962A5 (hr)
HRP20201055T1 (hr) Farmaceutske formulacije nitazoksanida s kontroliranim oslobađanjem
HRP20210749T1 (hr) Farmaceutski pripravci koji sadrže azd9291
JP6301934B2 (ja) チカグレロルを含む固形経口医薬製剤
US20120093738A1 (en) Taste-masked oral formulations of influenza antivirals
RU2006133902A (ru) Твердые препаративные формы оспемифена
HRP20201162T1 (hr) Farmaceutski sastav koji može uključiti lenalidomid u različitim kristaliničnim modifikacijama
HRP20161262T1 (hr) Tablete ulipristal acetata
SG10201407947WA (en) Compressible-coated pharmaceutical compositions and tablets and methods of manufacture
HRP20210668T1 (hr) Orodisperzibilna tableta koja sadrži estetrol
JP2010132654A5 (hr)
JP2007523210A5 (hr)
AR100977A1 (es) Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación
HRP20190550T1 (hr) Formule i metode proizvodnje formulacija za upotrebu u pražnjenju debelog crijeva
JP2018503611A5 (hr)
JP2021512869A5 (hr)
RU2014145931A (ru) Композиция для лечения нарушений метаболизма
UY33061A (es) Composiciones para comprimidos desintegrables oralmente de ondansetrón para prevenir náuseas y vómitos
ES2736155T3 (es) Comprimidos de otilonio por compresión directa
WO2016079687A1 (en) Oral pharmaceutical composition of teriflunomide
EP3513811A1 (en) Delayed release dosage forms comprising dimethyl fumarate
HRP20230437T1 (hr) Formulacija afabicina, postupak izrade iste